Core Insights - The company celebrates its 25th anniversary by declaring a special dividend of 15 Hong Kong cents per share [1][3] - Despite macroeconomic challenges, the company reported revenue growth of 5.9% year-on-year, reaching $83.6 million [2][3] - The company’s profit attributable to shareholders increased by 5.1% to $19.8 million, with core operating profit rising 11.4% to $15.1 million [2][3] Financial Performance - Revenue for the reporting period was $83.6 million, up 5.9% year-on-year [2] - Sales volume reached 919,000 units, with 779,000 units being proprietary products, reflecting an 8.6% increase [1] - Basic earnings per share increased to 2.40 US cents from 2.28 US cents in the first half of 2024 [2] Market Growth - The Asia-Pacific market saw a revenue increase of 14.0%, while Europe, the Middle East, and Africa (EMEA) grew by 17.0%, and the U.S. market grew by 20.0% [1][3] - The company has established a sales network covering over 70 countries and regions, with direct sales teams in 13 regions [4] Strategic Initiatives - The company acquired a Taiwanese distributor and plans to establish direct sales teams in Belgium and the Netherlands to enhance its presence in the Asia-Pacific and EMEA markets [1][3] - The company is leveraging its global commercialization expertise to form strategic partnerships with peers in the medical device industry, enriching its product portfolio [4] Product Development - The company holds over 250 authorized patents and has more than 55 approved products [4] - Clinical trials for several products are progressing, with expectations for new product launches in the U.S. and Japan [5] Production Capacity - The company has production bases in Shenzhen, the Netherlands, and Germany, with an annual production capacity of approximately 2.1 million units [5] - A new R&D and production facility in Hangzhou is expected to be operational by 2027, adding an annual capacity of 2.4 million units [5] Future Outlook - The company remains optimistic about the second half of 2025, anticipating continued growth in emerging markets and plans to shift some markets from distribution to direct sales [6] - The company aims to enhance its market influence in Europe and Japan while expanding its product coverage in China [6]
业聚医疗2025年中期业绩收入及纯利双双增长 分别达8,360万美元及1,980万美元